$3 million prize goes to developers of Ozempic-style drugs
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Five scientists who helped develop Ozempic-style drugs have been awarded a $3 million prize nicknamed the "Oscars of Science."
The Breakthrough Prizes are annual awards that aim to recognize "the world's top scientists working in the fundamental sciences," according to the official website for the prizes. Six awards are given, in total, covering accomplishments in fundamental physics, mathematics and the life sciences.
This year, Dr. Jens Holst, Dr. Daniel Drucker, Dr. Joel Habener, Lotte Knudsen and Svetiana Mojsov have been announced as joint winners of one of three Breakthrough Prizes in Life Sciences for 2025.
"When something [like this award] drops in completely unexpected, that's nice, that's wonderful," Holst, a professor of medical physiology at the University of Copenhagen, told Live Science.
Related: Scientists behind tech in mRNA vaccines snag 2nd prestigious prize — is a Nobel next?
Holst and his colleagues received one of the life-science awards this year "for the discovery and characterization of glucagon-like peptide 1 and revealing its physiology and potential in treating diabetes and obesity," read an official statement.
Glucagon-like peptide 1, or GLP-1, is a hormone that the gut secretes after eating. The hormone stimulates the release of insulin, which lowers blood sugar levels, and it also slows down digestion, making people feel full. It's a key player in how the brain regulates appetite.
Drugs like Ozempic and Wegovy are examples of "GLP-1 receptor agonists" — they mimic the action of the GLP-1 hormone in the body to treat type 2 diabetes and obesity, respectively.
These drugs have garnered significant popularity over the past decade, and they are now being investigated as potential treatments for many other health conditions, ranging from substance-use disorders to Alzheimer's disease. In 2024, Wegovy also got regulatory approval in the United States to treat heart disease, although questions remain regarding how it actually treats the condition.
However, despite their success, GLP-1 receptor agonists have also faced considerable scrutiny. For instance, there have been reports of some patients experiencing nasty side effects, such as persistent vomiting and stomach paralysis.
Additionally, a large study published in 2025 revealed that these drugs may reduce the risk of developing 42 health conditions but may increase the chances of experiencing 19 others, including abdominal pain, low blood pressure and arthritis. This study was correlational, so it's unknown if GLP-1 agonists are actually driving these conditions, but it still raises questions about the drugs' long-term effects.
Even with these concerns, though, many believe these drugs have revolutionized the treatment of cardiometabolic disorders. In the U.S., 1 in 8 adults have reported using a GLP-1 drug at some point in their lives.
Holst and colleagues originally discovered the GLP-1 hormone back in the 1980s. Piece by piece, they gathered data showing that the hormone stimulated insulin secretion, and that it inhibited food intake and the emptying of the stomach after a meal, Holst said.
Over the years, the researchers further examined these physiological effects within the context of diabetes and obesity, which eventually led to the development of the widely used drugs that are household names today.
There is likely a huge interest around these drugs because they offer an alternative, and very effective, route to weight loss for people with obesity who might not have found success with other interventions, Holst said. However, as a doctor, he is more interested in their ability to treat the knock-on health concerns tied to obesity, such as certain cancers and atherosclerosis, which can lead to coronary artery disease, he added.
"What we know is that obesity is associated with a hell of [a lot of] complications," he said. "The important thing is that with these compounds, you can prevent that."
Holst and colleagues are now investigating how the body regulates its own GLP-1 hormone levels and whether this process can be manipulated. For instance, they want to see whether patients with obesity or diabetes could be given a drug that increases the secretion of their own GLP-1 hormone, rather than being given a drug that just mimics the action of GLP-1, Holst said.
RELATED STORIES
—4 biologists awarded Germany's most prestigious scientific award, worth 2.5 million euros
—2 scientists win $3 million 'Breakthrough Prize' for mRNA tech behind COVID-19 vaccines
—2 scientists snag Nobel in medicine for discovering 'microRNAs'
In addition to the prize awarded to GLP-1's developers, the other two life sciences awards this year went to Dr. Stephen Hauser and Dr. Alberto Ascherio, for their work on multiple sclerosis, and David Liu for developing two common gene editing technologies known as "base editing" and "prime editing."
This year's winners will receive their awards at a ceremony in Los Angeles on April 5, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
NASA's Parker Solar Probe spots powerful magnetic explosion aimed at the sun's surface
When you buy through links on our articles, Future and its syndication partners may earn a commission. While making a death-defying dive through the sun's atmosphere, NASA's Parker Solar Probe has directly recorded a powerful plasma explosion heading toward our star's surface in unprecedented detail. Parker's new measurements found protons with about 1000 times greater energy than expected and a plasma jet shooting toward the sun, not away from it. Parker was uniquely positioned between the sun and the particles' source, allowing scientists to easily figure out where they came from. These findings indicate that the complexity and strength of tangles in the sun's magnetic field can accelerate charged particles to much greater speeds than expected from the field's strength alone. The sunward plasma jet was caused by "magnetic reconnection" in the sun's atmosphere — the explosive process in which magnetic fields fracture and reconnect. The powerful phenomenon transforms energy stored in the sun's magnetic field into energy that accelerates the solar wind — the constant stream of charged particles that the sun blasts across the solar system. Understanding magnetic reconnection is critical for making better predictions about space weather, which is driven by the solar wind and other energetic outbursts from our star. Space weather is a primary suspect for what stripped away Mars' atmosphere, turning it from a habitable planet into an icy desert wasteland. On Earth, space weather can trigger geomagnetic storms that cause blackouts, damage satellites, interfere with radio and GPS signals, and even put astronauts at risk. On the bright side, it also gives Earth its signature glorious auroras. The sun's magnetic field is extremely powerful, complex and dynamic. Space weather predictions require complicated computer simulations based on equations that describe how magnetic fields behave — but the sun is so large and convoluted that these equations will always be approximations. To improve the models' accuracy, scientists must collect extremely detailed measurements of the sun. This is where the Parker Solar Probe comes in. The Parker Solar Probe is the first mission to fly into the sun's upper atmosphere, called the corona. It has been directly measuring magnetic fields and particles in and around the corona in unprecedented detail, providing scientific insight into the heliosphere (the sun's atmosphere, which encompasses the entire solar system in a massive, elongated bubble). Related: NASA's daredevil solar spacecraft survives 2nd close flyby of our sun "These findings indicate that magnetic reconnection … is an important source of energetic particles in the near-Sun solar wind," lead study author Mihir Desai, director of the Southwest Research Institute's Department of Space Research, said in a statement. "Everywhere there are magnetic fields there will be magnetic reconnection. But the Sun's magnetic fields are much stronger near the star, so there's a lot more stored energy to be released." Understanding the workings of magnetic reconnection events could help scientists better predict harmful space weather, the researchers said. RELATED STORIES —New 8K-resolution photos of the sun show off incredible details of raging sunspots —Space photo of the week: Pink 'raindrops' on the sun captured in greatest detail ever —Powerful Mother's Day geomagnetic storm created radio-disrupting bubbles in Earth's upper atmosphere "Reports from the American Meteorological Society indicated that the powerful solar events in May 2024 wreaked havoc with farmers when extreme geomagnetic storms disrupted the precise GPS-guided navigation systems used to plant, fertilize and harvest rows of seeds, causing an estimated loss of up to $500 million in earning potential," Desai said. "Parker's access to this new data is critical, particularly as we remain in the midst of a very active solar cycle." The latest measurements of magnetic reconnection, reported in a paper published May 29 in The Astrophysical Journal Letters, are one of many new discoveries Parker has made. In 2023, over 700 peer-reviewed scientific papers were published using data collected in the probe's first four years of operation, and there are still many more discoveries to be made. The spacecraft completed its second ultra-close flyby of the sun on March 22, zooming within 3.8 million miles (6.1 million kilometers) of the sun's surface — matching its own record from December 2024.
Yahoo
2 hours ago
- Yahoo
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Shares have soared, but still have a ton of potential for patient long-term shareholders. 10 stocks we like better than Hims & Hers Health › Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
See the moon shine with famous red star Antares in the southern sky on June 9
When you buy through links on our articles, Future and its syndication partners may earn a commission. The waxing gibbous moon will shine close to the red star Antares in the constellation Scorpius on the night of June 9. Stargazers in the U.S. will find the moon rising higher over the southeastern horizon after sunset on June 9, with Antares shining brightly around 4 degrees to the lower left of the lunar disk. For context, your little finger held at arms length accounts for roughly 1 degree in the night sky, while your index, middle and ring fingers together amount to around 5 degrees, according to NASA. Antares is also known as the "Heart of the Scorpion" thanks to its prominent position in the zodiacal constellation Scorpius, which itself contains a number of stunning deep sky objects, such as the Messier 4 globular cluster and the closest stellar nursery to Earth — Rho Ophiuchi. As a red supergiant, Antares boasts a diameter 700 times greater than our sun and is known to shine roughly 10,000 times brighter. It is expected to end its life in a dramatic supernova explosion when it runs out of fuel — an event that could happen anytime from tomorrow to a million years or so from now. The lunar disk will appear to close in on Antares as the night of June 9 progresses, with the red star eventually setting above the moon's upper left shoulder as the duo slip beneath the southwestern horizon in the predawn hours of June 10. Viewers based in a number of southern hemisphere countries, including Australia, Tasmania and Papua New Guinea, will see the moon slide directly in front of Antares, blocking its light in an event known as an '"occultation" starting at 4:47 a.m. EDT (0847 GMT), according to Stargazers hoping to capture the majesty of the lunar surface should check out our handy guide detailing how to photograph the moon, while those looking for a closer view of the cosmos should read our lists of the best telescopes and binoculars for exploring the night sky. Editor's Note: If you happen to capture a picture of the moon and Antares and want to share it with readers, then please send your photo(s), comments, and your name and location to spacephotos@
